NEW DELHI: Following Pfizer and Serum Institute, Hyderabad-based pharmaceutical firm Bharat Biotech submitted a request to the central drug regulator on Monday for an emergency use authorization for its Covid-19 Covaxin vaccine, official sources said.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
On December 4, Prime Minister Narendra Modi at a meeting of all parties expressed his hope that a Covid-19 vaccine will be ready in a few weeks.
That same night, the Indian arm of the US pharmaceutical giant Pfizer applied to the central drug regulator for emergency use approval for its vaccine, after the company obtained such authorization in the United Kingdom and Bahrain.
The Serum Institute sought that go-ahead for the Oxford Covid-19 vaccine, Covishield, on December 6.
Bharat Biotech, Serum Institute of India and Pfizer applications will be reviewed by the Covid-19 Expert Committee (SEC) at the Central Drugs Standard Control Organization (CDSCO) in the coming days.
“However, so far none of the applications have been sent to the committee and no date has been set on when the SEC will meet to evaluate and evaluate the applications,” the official source said.
Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
On December 4, Prime Minister Narendra Modi at a meeting of all parties expressed his hope that a Covid-19 vaccine will be ready in a few weeks.
That same night, the Indian arm of the US pharmaceutical giant Pfizer applied to the central drug regulator for emergency use approval for its vaccine, after the company obtained such authorization in the United Kingdom and Bahrain.
The Serum Institute sought that go-ahead for the Oxford Covid-19 vaccine, Covishield, on December 6.
Bharat Biotech, Serum Institute of India and Pfizer applications will be reviewed by the Covid-19 Expert Committee (SEC) at the Central Drugs Standard Control Organization (CDSCO) in the coming days.
“However, so far none of the applications have been sent to the committee and no date has been set on when the SEC will meet to evaluate and evaluate the applications,” the official source said.
.
